Image Following Treatment with 177Lu-PSMA-617 Selected by Society of Nuclear Medicine and Molecular Imaging as Image of the Y...
June 26 2018 - 7:00PM
Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company
developing targeted therapeutics for personalized cancer treatment,
today announced that an image from a Phase 2 study of
177Lu-PSMA-617, led by Dr. Michael Hofman of the Peter McCallum
Cancer Centre in Melbourne, Australia, was selected at the Society
of Nuclear Medicine and Molecular Imaging Annual Meeting as the
“Image of the Year.” The image depicts the positron emissions
tomography (PET) scans of eight patients before treatment with
177Lu-PSMA-617 and at three months following treatment.
“This recognition reflects the potential of 177Lu-PSMA-617 and
radioligand therapies to be a new treatment modality for patients
with metastatic castration-resistant prostate cancer (mCRPC).” said
Mike Sherman president and CEO of Endocyte. “We are grateful to
SNMMI for this award and to Dr. Michael Hofman for his work with
177Lu-PSMA-617. We are continuing to enroll patients with mCRPC in
the Phase 3 VISION trial to confirm the promising results seen in
earlier trials.”
Dr. Hofman, a clinical investigator in the study, said,
“recognition of this image as Image of the Year underscores the
potential impact that targeting 177Lu to PSMA-positive disease has
had in these patients. This recognition encourages us to
continue our research at Peter MacCallum Cancer Centre in a
50-patient single arm Phase 2 study and the 200 patient TheraP
Phase 2 study.”
A photo accompanying this announcement is available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/a721f857-695c-47cb-bca2-93615ac49880
Website Information
Endocyte routinely posts important information
for investors on its website, www.endocyte.com, in the “Investors
& News” section. Endocyte uses this website as a means of
disclosing material information in compliance with its disclosure
obligations under Regulation FD. Accordingly, investors should
monitor the “Investors & News” section of Endocyte’s website,
in addition to following its press releases, SEC filings, public
conference calls, presentations and webcasts. The information
contained on, or that may be accessed through, Endocyte’s website
is not incorporated by reference into, and is not a part of, this
document.
About Endocyte
Endocyte is a biopharmaceutical company and leader in developing
targeted therapies for the personalized treatment of cancer. The
company's drug conjugation technology targets therapeutics and
companion imaging agents specifically to the site of diseased
cells. Endocyte's lead program is a prostate specific membrane
antigen (PSMA)-targeted radioligand therapy, 177Lu-PSMA-617, in
phase 3 for metastatic castration resistant prostate cancer
(mCRPC). Endocyte is also advancing its adaptor-controlled CAR
T-cell therapy into the clinic in 2018, where it will be studied in
osteosarcoma. For additional information, please visit Endocyte's
website at www.endocyte.com.
Forward Looking Statements
Certain of the statements made in this press release are forward
looking, such as those, among others, relating to the company's
future development plans including those relating to the completion
of pre-clinical development in preparation for possible future
clinical trials, the anticipated initiation of a registration
trial, and preparation for potential commercialization. Actual
results or developments may differ materially from those projected
or implied in these forward-looking statements. Factors that may
cause such a difference include risks that the company or
independent investigators may experience delays in the initiation
or completion of clinical trials (whether caused by competition,
adverse events, patient enrollment rates, shortage of clinical
trial materials, regulatory issues or other factors); risks that
data from prior clinical trials may not be indicative of subsequent
clinical trial results; risks related to the safety and efficacy of
the company’s product candidates; risks that early stage
pre-clinical data may not be indicative of subsequent data when
expanded to additional pre-clinical models or to subsequent
clinical data; risks that evolving competitive activity and
intellectual property landscape may impair the company's ability to
capture value for the technology; risks that expectations and
estimates turn out to be incorrect, including estimates of the
potential markets for the company’s product candidates, estimates
of the capacity of manufacturing and other facilities required to
support its product candidates, projected cash needs, and expected
future revenues, operations, expenditures and cash position. More
information about the risks and uncertainties faced by Endocyte,
Inc. is contained in the company’s periodic reports filed with the
Securities and Exchange Commission. Endocyte, Inc. disclaims any
intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Investor Contact:Michael Schaffzin, Stern
Investor Relations, Inc., (212) 362-1200,
michael@sternir.com
Endocyte, Inc. (delisted) (NASDAQ:ECYT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Endocyte, Inc. (delisted) (NASDAQ:ECYT)
Historical Stock Chart
From Sep 2023 to Sep 2024